Effect of Gabapentin on Pain of the Second Cataract Surgery
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02127853 |
Recruitment Status : Unknown
Verified April 2014 by Hee-Pyoung Park, Seoul National University Hospital.
Recruitment status was: Recruiting
First Posted : May 1, 2014
Last Update Posted : May 12, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hyperalgesia | Drug: gabapentin Drug: placebo | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 70 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | The Effect of Pretreated Gabapentin on Hyeralgesia Occurring in the Second Operation in Staged Bilateral Cataract Surgery |
Study Start Date : | July 2014 |
Estimated Primary Completion Date : | February 2016 |
Estimated Study Completion Date : | February 2016 |
Arm | Intervention/treatment |
---|---|
Experimental: Gabapentin
gabapentin pretreatment
|
Drug: gabapentin
100 mg tid of gabapentin is prescribed to the patient for 1 week after the first eye surgery |
Placebo Comparator: Placebo
placebo drug pretreatment
|
Drug: placebo
the same regimen of placebo drug is prescribed to the patient for 1 week after the first eye surgery |
- proportion of subjects who answer that "pain was greater" in the second eye surgery [ Time Frame: Intra operative (pain while fluid injection to anterior chamber) ]
- perioperative pain [ Time Frame: end of surgery, post-op 1hr at PACU, at out-patient ward, post-op 1 day ]evaluation of overall perioperative pain
- satisfaction [ Time Frame: intra operative ]evaluation of satisfaction of both operator and patient
- anxiety [ Time Frame: baseline (at OR room arrival, just before sterile draping) ]evaluation of patient's anxiety

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patient of ASA(American Cociety of Anesthesiology) class I, II, III between age 20 to 80, scheduled for serial bilateral cataract surgery(1 weel interval)
Exclusion Criteria:
- refuse to participate
- BMI<16 or BMI >30
- severe cardiovascular, pulmonary, renal disease
- alcohol or drug abuse
- currently taking CNS(central nervous system) inhibitory drugs
- taking antiacids
- depressive disorder pregnancy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02127853
Contact: Heepyoung Park, MD,PhD | 82-2-2072-2466 | hppark@snu.ac.kr | |
Contact: Eugene Kim, MD | 82-2-2072-2469 | tomomie@hanmail.net |
Korea, Republic of | |
Seoul National University Hospital | Recruiting |
Seoul, Korea, Republic of, 110-799 | |
Contact: Heepyoung Park, MD, PhD 82-2-2072-2466 hppark@snu.ac.kr | |
Contact: Eugene Kim, MD 82-2-2072-2469 tomomie@hanmail.net |
Responsible Party: | Hee-Pyoung Park, associate professor, Seoul National University Hospital |
ClinicalTrials.gov Identifier: | NCT02127853 |
Other Study ID Numbers: |
SerialCataractGaba |
First Posted: | May 1, 2014 Key Record Dates |
Last Update Posted: | May 12, 2015 |
Last Verified: | April 2014 |
serial cataract surgery hyperalgesia gabapentin central sensitization |
Hyperalgesia Cataract Lens Diseases Eye Diseases Somatosensory Disorders Sensation Disorders Neurologic Manifestations Nervous System Diseases Gabapentin Analgesics Sensory System Agents Peripheral Nervous System Agents |
Physiological Effects of Drugs Anticonvulsants Anti-Anxiety Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Antimanic Agents |